Precipio, Inc. (PRPO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, operating CLIA-certified laboratories in New Haven, Connecticut, and Omaha, Nebraska. The company develops diagnostic products and services to address cancer misdiagnoses. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $6.77 million | $5.21 million | $17.35 million | $13.08 million |
| Gross Profit | $3.01 million | $2.28 million | $7.57 million | $4.91 million |
| Gross Margin | 44% | 44% | 44% | 38% |
| Operating Loss | $(0.06) million | $(0.60) million | $(1.74) million | $(3.88) million |
| Net Loss | $(0.08) million | $(0.63) million | $(0.89) million | $(3.93) million |
| Cash and Equivalents | $2.31 million (as of Sept 30, 2025) | |||
| Working Capital | $1.22 million (as of Sept 30, 2025) | |||
| Total Debt (Current + Long Term) | $0.09 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30% quarter-over-quarter and 33% year-to-date, driven primarily by a 19% increase in diagnostic testing cases (4,258 cases in Q3 2025 vs. 3,584 in Q3 2024).
- Profitability Improvement: The operating loss narrowed significantly to $61,000 in Q3 2025 from $597,000 in Q3 2024. Year-to-date operating loss decreased to $1.74 million from $3.88 million.
- Non-Recurring Income: The YTD 2025 net loss was significantly reduced by $0.8 million in Employee Retention Credit (ERC) income and a $0.14 million gain on liability settlement. Excluding these items, the company remains in an operating loss position.
- Liquidity: Cash balances increased from $1.39 million at year-end 2024 to $2.31 million in Q3 2025, largely due to $1.26 million in proceeds from warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has disclosed substantial doubt about the company's ability to continue as a going concern for the next 12 months. This is due to an accumulated deficit of $103.3 million and a history of operating losses. Continued operations depend on achieving business plans and raising additional financing.
- Unusual Items:
- Employee Retention Credit (ERC): Received $0.8 million in Q2 2025; $0.7 million remains outstanding with no assurance of timing or receipt.
- Change Healthcare (CHC) Impact: The company received $1.1 million in temporary funding assistance from CHC following a 2024 cyberattack. As of Q3 2025, $0.3 million remains payable to CHC, with monthly repayments scheduled through January 2026. A $0.1 million portion was written off in May 2025.
- Capital Actions: In Q3 2025, the company received approximately $1.3 million from the exercise of 100,000 warrants. The "At the Market" (ATM) offering agreement was terminated on September 2, 2025.
- Risks: Key risks include reliance on third-party payers (Medicare/Medicaid), potential changes in tax law (One Big Beautiful Bill Act of 2025), and geopolitical instability affecting trade and supply chains.
Investor Verification Checklist
- Going Concern Status: Verify the company's specific plan to secure additional financing to meet debt obligations and operational costs over the next 12 months.
- ERC Collectability: Assess the likelihood and timing of receiving the remaining $0.7 million in Employee Retention Credits.
- CHC Repayment Schedule: Confirm the impact of the $0.3 million remaining liability to Change Healthcare on future cash flows.
- Revenue Concentration: Note that one customer (Customer A) accounted for 27% of Q3 2025 net sales and 26% of accounts receivable.
- Warrant Exercises: Monitor the remaining 31,944 outstanding warrants and the potential for cashless exercises which would not provide liquidity.